Identification of novel cellular transcription factors that regulate early promoters of human papillomavirus types 18 and 16

Journal of Infectious Diseases

Volumn 206, Issue 6, 2012, Pages 867-874

  Sichero, Laura ^a,b   Sobrinho, João Simão ^a,b   Villa, Luisa Lina ^a,b,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b Instituto do Cancer do Estado de Sao Paulo   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LUCIFERASE; MYC PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BINDING SITE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE INTERACTION; GENE SEQUENCE; GENETIC DATABASE; GENETIC TRANSFECTION; GENETIC VARIABILITY; HIGH THROUGHPUT TRANSFECTION ARRAY; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; VIRAL GENETICS; VIRUS EXPRESSION; VIRUS LONG CONTROL REGION; VIRUS STRAIN;

CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, VIRAL; GENETIC VARIATION; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOBLOTTING; PROMOTER REGIONS, GENETIC; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84865781750     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jis430     Document Type: Article

References (35)

1. Walboomers JMM, Jacobs MV, Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-9.
2. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks to humans. Vol. 90. Smokeless tobacco products. Lyon, France: IARC, 2007; 689.
3. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virol 2004; 324:17-27.
4. Bernard HU. Gene expression of genital human papillomavirus and considerations on potential antiviral approaches. Antivir Ther 2002; 7:219-37.
5. Ho L, Chan SY, Burk RD, et al. The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations. J Virol 1993; 67:6413-23.
6. Ong CK, Chan SY, Campo MS, et al. Evolution of human papillomavirus type 18: an ancient phylogenetic root in Africa and intratype diversity reflect coevolution with human ethnic groups. J Virol 1993; 67:6424-31.
7. Chen Z, Terai M, Fu L, Herrero R, DeSalle R, Burk RD. Diversifying selection in human papillomavirus type 16 lineages based on complete genome analyses. J Virol 2005; 79:7014-23.
8. Sichero L, Villa LL. Epidemiological and functional implications of molecular variants of human papillomavirus. Braz J Med Biol Res 2006; 39:707-17.
9. Villa LL, Schlegel R. Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region. Virol 1991; 181:374-7.
10. Münger K, Phelps WC, Bubb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989; 63:4417-21.
11. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505.
12. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV 16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989; 8:3905-10.
13. Dürst M, Kleinheinz A, Hotz M, Gissmann L. The physical state of human papillomavirus type 16 in benign and malignant genital tumors. J Gen Virol 1985; 66:1515-22.
14. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2:342-50.
15. Carson A, Khan SA. Characterization of transcription factor binding to human papillomavirus type 16 DNA during cellular differentiation. J Virol 2006; 80:4356-62.
16. Garcia-Vallvé S, Iglesias-Rozas JR, Alonso A, Bravo IG. Different papillomaviruses have different repertoires of transcription factor binding sites: convergence and divergence in the upstream regulatory region. BMC Evol Biol 2006; 6:1-14.
17. Sichero L, Ferreira S, Trottier H, et al. High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007; 120:1763-8.
18. Xi LF, Koutsky LA, Hildesheim A, et al. Risk for high-grade cervical intraepithelial neoplasia associated with variants of human papillomavirus types 16 and 18. Cancer Epidemiol Biomarkers Prev 2007; 16:4-10.
19. Kämmer C, Warthorst U, Torres-Martinez N, Wheller CW, Pfister H. Sequence analysis of the long control region of human papillomavirus type 16 variants and functional consequences for p97 promoter activity. J Gen Virol 2000; 81:1975-81.
20. Sichero L, Franco EL, Villa LL. Different P105 promoter activity among natural variants of human papillomavirus type 18. J Infect Dis 2005; 191:739-42.
21. Wingender E, Dietze P, Karas H, Knüppel R. TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996; 24:238-41.
22. Huang Q, Raya A, DeJesus P, et al. Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci 2004; 101:3456-61.
23. Liu J, Bang AG, Kintner C, et al. Identification of the Wnt signaling activator leucine-rich repeat in flightless interaction protein 2 by a genome-wide functional analysis. Proc Natl Acad Sci 2005; 102: 1927-32.
24. O'Connor M, Chan SY, Bernard HU. Transcription factor binding sites in the long control region of genital HPVs. In: Myers G, Delius H, Icenogel J, Bernard HU, Baker C, Halpern A. Human papillomaviruses. A compilation and analysis of nucleic acid and aminoacid sequences. Los Alamos, New Mexico: Los Alamos National Laboratory, 1995:III21-41.
25. Zhao W, Chow LT, Broker TR. Transcription activities of human papillomavirus type 11 E6 promoter-proximal elements in raft and submerged cultures of foreskin keratinocytes. J Virol 1997; 71:8832-40.
26. Steenbergen RD, OudeEngberink VE, Kramer D, et al. Downregulation of GATA-3 expression during human papillomavirus-mediated immortalization and cervical carcinogenesis. Am J Pathol 2002; 160:1945-51.
27. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001; 14:78-85.
28. Beger M, Butz K, Denk C, Williams T, Hurst HC, Hoppe-Seyler F. Expression pattern of AP-2 transcription factors in cervical cancer cells and analysis of their influence on human papillomavirus oncogene transcription. J Mol Med 2001; 79:314-20.
29. Somasundaram K, Reddy SP, Vinnakota K, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005; 24:7073-83.
30. Macfarlan T, Kutney S, Altman B, Montross R, Yu J, Chakravarti D. Human THAP7 is a chromatin-associated, histone tail-binding protein that represses transcription via recruitment of HDAC3 and nuclear hormone receptor corepressor. J Biol Chem 2005; 280:7346-58.
31. Nilsson JA, Cleveland JL. MYC pathways provoking cell suicide and cancer. Oncogene 2003; 22:9007-21.
32. Wu KJ, Grandori C, Amacker M, et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21:220-4.
33. Higareda-Almaraz JC, Enriquez-Gasca MD, Hernandez-Ortiz M, Resendis-Antonio O, Encarnacion-Guevara S. Proteomic patterns of cervical cancer cell lines, a network perspective. BMC Syst Biol 2011; 5:96.
34. Friedman JR, Kaestner KH. The FoxA family of transcription factors in development and metabolism. Cell Mol Life Sci 2006; 63: 2317-28.
35. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer 2007; 120:1013-22.